REYKJAVIK, Iceland, March 30, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Alvotech Annual Report 2025. The report is available on the SEC’s website, www.sec.gov, as well as in the investor relations section of Alvotech’s website at https://investors.alvotech.com/financials. For further information, contact: MediaBenedik ...

Core Viewpoint - Alvotech will release its fourth quarter and full year 2025 financial and operating results on March 18, 2026, after U.S. markets close [1] - A conference call with a live Q&A session is scheduled for March 19, 2026, at 08:00 EST [2] Company Overview - Alvotech is a biotechnology company focused on developing and manufacturing biosimilar medicines globally [4] - The company aims to be a leader in the biosimilar market by providing high-quality, cost-effective products through a fully integrated approach [4] - Currently, five biosimilars are approved and marketed, including those for Humira, Stelara, Simponi, Eylea, and Prolia/Xgeva [4] - The development pipeline includes nine disclosed biosimilar candidates targeting various conditions such as autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer [4] - Alvotech has established strategic commercial partnerships to enhance its global reach and leverage local expertise across multiple regions, including the U.S., Europe, Japan, China, and parts of South America, Africa, and the Middle East [4]